Skip to main content

Advertisement

SpringerLink
Log in

Tissue thioredoxin reductase-1 expression in astrocytomas of different grades

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Thioredoxin (Trx) is a redox active protein that regulates several physiological and biochemical functions, such as growth, apoptosis and cellular defense. The function of Trx itself is regulated by thioredoxin reductase (TrxR). Studies performed in a variety of human primary tumors have shown that thioredoxin reductase 1 (TrxR1) is overexpressed in tumoral tissues compared with corresponding normal tissues. This study was designed to determine the expression of TrxR1 in astrocytoma tissues of different World Health Organization (WHO) grades (grade I–IV). The proliferative (Ki-67) and apoptotic indices of the specimens were also investigated for correlation analysis. Astrocytoma tissues were extracted from the histopathological specimens of 40 patients. These samples included seven histologically normal brain tissues that served as a control group and ten tumoral samples for each grade of astrocytoma (grade I–IV). The histologically normal brain tissues were obtained from the non-tumoral portions of the pathological specimens of grade I (2 cases), grade II (2 cases), grade III (2 cases) and grade IV (1 case) astrocytomas. TrxR1 expression was evaluated using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunostaining. The proliferative and apoptotic indices of the specimens were investigated by Ki-67 immunostaining and TUNEL assay, respectively. TrxR1 expression, as assessed by qRT-PCR, increased significantly with astrocytoma grade (p = 0.01). The immunostaining intensity of TrxR1 in grade IV astrocytomas was significantly greater than that in the control tissue and all other astrocytoma grades (p < 0.001). Similarly, immunostaining intensity of TrxR1 in the grade III astrocytomas was significantly greater than that in the control group and grade I astrocytomas (p < 0.001). All astrocytoma tissues showed more intense staining in ascending grades, but the differences between grade I and the control, grade II and the control, grades II and I, grades III and II were not statistically significant (p > 0.05). Ki-67 index values increased significant in accordance with grade progression (p = 0.01). The apoptotic index values were not significantly different in any group (p > 0.05); however, the differences between grade IV and the control and between grades IV and I were statistically significant (p < 0.05). Expression of TrxR1, as assessed by both qRT-PCR and immunostaining, correlated highly with both the astrocytoma grade and Ki-67 index.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lee SG, Kim K, Kegelman TP, Dash R, Das SK, Choi JK, Emdad L, Howlett EL, Jeon HY, Su ZZ, Yoo BK, Sarkar D, Kim SH, Kang DC, Fisher PB (2011) Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity. Cancer Res 15–71(20):6514–6523

    Article  Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumors of the central nervous system. IARC Press, Lyon

    Google Scholar 

  3. Huang T, Jin X, He L, Zhang M, Wu J, Wang Y, Fang J (2013) Role of podocalyxin in astrocytoma: clinicopathological and in vitro evidence. Oncol Lett 6(5):1390–1396

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Haapasalo H, Kyläniemi M, Paunul N, Kinnula VL, Soini Y (2003) Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol 13(2):155–164

    Article  CAS  PubMed  Google Scholar 

  5. Kemerdere R, Kacira T, Hanimoglu H, Kucur M, Tanriverdi T, Canbaz B (2013) Tissue and plasma thioredoxin reductase expressions in patients with glioblastoma multiforme. J Neurol Surg Part A 74(4):234–238

    Article  Google Scholar 

  6. Yagublu V, Arthur JR, Babayeva SN, Nicol F, Post S, Keese M (2011) Expression of selenium-containing proteins in human colon carcinoma tissue. Anticancer Res 31(9):2693–2698

    CAS  PubMed  Google Scholar 

  7. Biaglow JE, Miller RA (2005) The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 4:6–13

    Article  CAS  PubMed  Google Scholar 

  8. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G (1996) Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16:3459–3466

    CAS  PubMed  Google Scholar 

  9. Powis G, Kirkpatrick DL, Angulo M, Baker A (1998) Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 111–112:23–34

    Article  PubMed  Google Scholar 

  10. Welsh SJ, Bellamy WT, Briehl MM, Powis G (2002) The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1 alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62:5089–5095

    CAS  PubMed  Google Scholar 

  11. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC, Harris AL (2001) Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7:3087–3091

    CAS  PubMed  Google Scholar 

  12. Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR, Kim JR (2002) Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22:3331–3335

    CAS  PubMed  Google Scholar 

  13. Järvelä S, Bragge H, Paunu N, Järvelä T, Paljärvi L, Kalimo H, Helén P, Kinnula V, Soini Y, Haapasalo H (2006) Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. J Neurooncol 77:131–140

    Article  PubMed  Google Scholar 

  14. Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, Mehta M, Curran W, Phan SC (2007) Results of the phase I doseescalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69:831–838

    Article  CAS  PubMed  Google Scholar 

  15. Ahmadi R, Urig S, Hartmann M, Helmke BM, Koncarevic S, Allenberger B, Kienhoefer C, Neher M, Steiner HH, Unterberg A, Herold-Mende C, Becker K (2006) Antiglioma activity of 2,2′:6′,2″-terpyridineplatinum[II] complexes in a rat model-effects on cellular redox metabolism. Free Radic Biol Med 40:763–778

    Article  CAS  PubMed  Google Scholar 

  16. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  CAS  PubMed  Google Scholar 

  17. Arnér ES, Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16:420–426

    Article  PubMed  Google Scholar 

  18. Nordberg J, Arnér ES (2001) Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31(11):1287–1312

    Article  CAS  PubMed  Google Scholar 

  19. Söderberg A, Sahaf B, Rosén A (2000) Thioredoxin reductase, a redoxactive selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res 60:2281–2289

    PubMed  Google Scholar 

  20. Albesiano E, Han JE, Lim M (2010) Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am 21(1):17–29

    Article  PubMed  Google Scholar 

  21. Iwasawa S, Yamano Y, Takiguchi Y, Tanzawa H, Tatsumi K, Uzawa K (2011) Upregulation of thioredoxine reductase 1 in human oral squamous cell carcinoma. Oncol Rep 25(3):637–644

    CAS  PubMed  Google Scholar 

  22. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, Kohno K (1995) Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55:4293–4296

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Meram Faculty of Medicine, Necmettin Erbakan University, Akyokus/Meram, 42080, Konya, Turkey

    Hasan Esen

  2. Department of Neurosurgery, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

    Fatih Erdi, Bulent Kaya & Fatih Keskin

  3. Department of Microbiology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

    Bahadır Feyzioglu

  4. Department of Public Health, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

    Lutfi Saltuk Demir

Authors
  1. Hasan Esen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatih Erdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bulent Kaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bahadır Feyzioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fatih Keskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lutfi Saltuk Demir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hasan Esen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esen, H., Erdi, F., Kaya, B. et al. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades. J Neurooncol 121, 451–458 (2015). https://doi.org/10.1007/s11060-014-1661-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1661-5

Keywords

Search

Navigation